Incyte has reported positive results from a Phase II trial of ruxolitinib cream for the treatment of adult patients aged 18 to 75 with vitiligo, a chronic, immune-mediated skin disease.

The randomised, double-blind, dose-ranging, vehicle-controlled, Phase II study (NCT03099304), which evaluated the safety and efficacy of the nonsteroidal, anti-inflammatory, JAK inhibitor therapy, met its primary endpoint.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study demonstrated that significantly more patients treated with ruxolitinib cream for a period of 24 weeks achieved a >50% improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with vehicle control (non-medicated cream).

Incyte chief medical officer Steven Stein “The positive 24-week data presented at the World Congress of Dermatology support the potential of ruxolitinib cream to offer a novel treatment option for patients with this chronic autoimmune disease.

“For patients who choose to seek treatment for their vitiligo, current options are often limited by inadequate efficacy or potential side effects.”

The highest F-VASI50 response in the study was achieved with ruxolitinib cream 1.5% once daily (QD) and twice daily (BID) compared to vehicle control.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Incyte noted that Ruxolitinib cream was generally well-tolerated at all dosage strengths.

Based on the positive data, the company plans to initiate the pivotal Phase III development later this year and preparations are currently underway.

The Phase II trial started in April 2017 and consists of three parts spanning 104 weeks.

The study’s primary efficacy endpoint was the percentage of patients treated with ruxolitinib, while key secondary endpoints included the proportion of patients who achieved a F-PhGVA score of zero or one at Week 24 and the safety and tolerability of ruxolitinib.